Lexaria Bioscience Reports Revenue Decline and Improved Net Loss for Six Months Ended February 28, 2026

Lexaria Bioscience Corp. reported a significant decline in revenue for the six months ended February 28, 2026, generating only $20,000 compared to $357,923 during the same period in 2025. This drop is attributed to the expiration of a licensing contract with Premier Anti-Aging Co., Ltd. and a strategic shift away from business-to-business (B2B) sales towards a focus on pharmaceuticals. The company incurred a net loss of $3.05 million for the current period, a notable improvement from the $5.42 million loss reported in the previous year, reflecting a reduction in operating expenses, particularly in research and development.

Total operating expenses decreased to $3.05 million from $5.80 million year-over-year, primarily due to a significant reduction in research and development costs, which fell from $3.64 million to $1.15 million. This decrease is linked to the completion of the Phase 1b Clinical Trial (GLP-1-H24-4) in December 2025. General and administrative expenses also saw a decline, contributing to the overall reduction in losses. The company’s cash position improved, with cash and cash equivalents rising to approximately $5.13 million as of February 28, 2026, compared to $1.80 million at the end of August 2025.

In terms of strategic developments, Lexaria raised $6.5 million in net proceeds from the sale of common stock through two registered direct offerings in late 2025. This capital infusion is intended to support ongoing research and development activities, particularly in the pharmaceutical sector, where the company is focusing on its proprietary DehydraTECH technology. The company has also extended its Material Transfer Agreement with a pharmaceutical partner, allowing for continued collaboration on clinical development.

Operationally, Lexaria's total assets increased to $6.49 million from $4.18 million, while total liabilities decreased significantly from $1.57 million to $0.28 million, indicating improved financial health. The company reported a decrease in accounts payable and accrued liabilities, which fell from $1.46 million to $0.18 million. However, the company continues to face challenges, as it has accumulated a deficit of $66.5 million and anticipates ongoing operational losses in the near future.

Looking ahead, Lexaria acknowledges substantial doubt regarding its ability to continue as a going concern within the next year, primarily due to its recurring losses and reliance on future financing. The company plans to pursue additional equity financing and strategic partnerships to support its operations and research initiatives. Management has indicated that while current cash resources are expected to fund operations through the first quarter of fiscal year 2027, further capital will be necessary to meet long-term financial obligations and continue its research programs.